TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15128963
Drug: Multisystemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisystemic therapy
Study: 17144179
Drug: Revisiting market
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revisiting market and regulatory incentives regarding race in medicine
Study: 11346808
Drug: 40 microg
Normalized name: Travoprost 40 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 microg parathyroid hormone (1-34)
Study: 3325488
Drug: Glucose polymers
Normalized name: glucose polymers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose polymers (3 g/kg)
Study: 10053177
Drug: Bupropion and
Normalized name: bupropion and naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion and nicotine patch
Study: 18792548
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate 1.2%-tretinoin 0.025% gel (CLIN/RA)
Study: 18792548
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate gel 1.2% (CLIN) monotherapy
Study: 29226465
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy at 6 L min‐1 for 6‐12 h
Study: 26817716
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil providing 0.7 g EPA+DHA/d
Study: 29962339
Drug: Thiazide therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide therapy
Study: 21187189
Drug: alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-lipoic acid 1800 mg/d
Study: 21187189
Drug: alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-lipoic acid 1200 mg/d
Study: 27225735
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg intravenous dexketoprofen prior to surgical incision
Study: 27225735
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg intravenous dexketoprofen 10 minutes after incision
Study: 1944470
Drug: Synthetic surfactant
Normalized name: Synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue
DrugBank: CHF5633 (DB18696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic surfactant (Exosurf, 5 ml/kg body weight)
Study: 8122302
Drug: No-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment group (placebo)
Study: 29846770
Drug: Ilaprazole 10
Normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 10 mg alone
Study: 29846770
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (Ilaprazole 10 mg, Clarithromycin 500 mg, Amoxicillin 1000 mg)
Study: 1388092
Drug: etodolac 600
Normalized name: etodolac 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etodolac 600 mg/day
Study: 28492612
Drug: Topical intranasal
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical intranasal corticosteroid therapy (nasal spray)
Study: 12499331
Drug: Carbohydrate-rich breakfast
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-rich breakfast (69.9 g carbohydrate and 5.2 g protein)
Study: 11736884
Drug: Intravenous tropisetron
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tropisetron (2 mg)
Study: 16962481
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic with EMLA (eutectic mixture of lidocaine and prilocaine)
Study: 28724883
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (1000 mg) 3 times a day for 3 days
Study: 10073740
Drug: GI198745 (dutasteride)
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GI198745 (dutasteride) 0.01 to 40 mg single oral doses
Study: 27792020
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (3 times/week for 6 weeks)
Study: 9065178
Drug: Pereyra suspension
Normalized name: Myrospermum pereirae wood oil
DrugBank: Balsam of Peru (DB11482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pereyra suspension
Study: 21219106
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 2% lidocaine
Study: 12228196
Drug: Low-dose involved-field
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose involved-field radiotherapy (LD-IFRT)
Study: 8281875
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg/day
Study: 9459113
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 190 mg/kg/day
Study: 9560175
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy plus graded exposure
Study: 356683
Drug: Flunisolide nasal
Normalized name: flunisolide nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide nasal spray (150 microgram/day)
Study: 10772184
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of oral glutamine daily
Study: 10090348
Drug: Nisoldipine CC
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine CC (10 mg to 40 mg daily)
Study: 9249116
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of ITS
Study: 23321647
Drug: β‐blockade and
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐blockade and losartan (BB-L)
Study: 10227003
Drug: Systemic hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic hormone replacement therapy (HRT)
Study: 1662959
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg itraconazole once a day
Study: 1662959
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ketoconazole twice a day
Study: 6161788
Drug: Alcohol alone
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol alone (0.4 g/kg and 0.8 g/kg)
Study: 25090264
Drug: Increasing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing the dose of metformin (500 mg/day)
Study: 7591280
Drug: FEC+G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC+G-CSF
Study: 24622423
Drug: Concurrent rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent rehabilitation (CON)
Study: 1952204
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl infusion
Study: 6636394
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prophylactic antimicrobial therapy)
Study: 20214831
Drug: JinQi-Jiangtang tablets
Normalized name: Jianghuang
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JinQi-Jiangtang tablets (JQJT)
Study: 21332729
Drug: Granulocyte-colony-stimulating factor
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Granulocyte-colony-stimulating factor (G-CSF) injection in lower adipose tissue-containing sites (arms and legs) (Group B)
Study: 17692723
Drug: Tretinoin gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel microspheres 0.1%
Study: 18390085
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not explicitly defined, but implied as no treatment)
Study: 11060833
Drug: Intravenous parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intravenous parecoxib
Study: 12495686
Drug: PMX-F and
Normalized name: F-15599
DrugBank: F-15599 (DB16936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMX-F and teicoplanin in combination (N=20)
Study: 20938423
Drug: Klamath algae
Normalized name: Mastocarpus stellatus algae extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Klamath algae extract (Klamin®, 1600 g/day)
Study: 19487582
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs
Study: 29606522
Drug: Concurrent and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent and adjuvant temozolomide chemotherapy
Study: 28138828
Drug: Docetaxel combined
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel combined with resminostat (DR) therapy
Study: 24656944
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray formulation containing 0.2% sodium hyaluronate alone
Study: 91436
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy (MCT) with CCNU, methotrexate, and vinblastine for 2 years
Study: 26861858
Drug: IV enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV enoxaparin 0.5 mg/kg
Study: 23153449
Drug: RSV fusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RSV fusion protein nanoparticle vaccine
Study: 12394544
Drug: Both solutions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both solutions
Study: 9801179
Drug: Prochlorperazine maleate,
Normalized name: Prochlorperazine Maleate, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine maleate, 10 mg intramuscularly
Study: 21541462
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) vaccine administration (40 mg/dose)
Study: 8194687
Drug: Cyclosporine enemas
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine enemas (350 mg nightly for 4 weeks)
Study: 31302767
Drug: Oral cryotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cryotherapy during the whole course of cytotoxic agents administration (arm A)
Study: 31302767
Drug: Regular oral
Normalized name: infant formula,regular ORAL PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular oral cryotherapy twice a day (arm C)
Study: 10880891
Drug: 267 mg
Normalized name: urea 267 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 267 mg micronised fenofibrate
Study: 17429632
Drug: Continuous 6-hour
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 6-hour infusion of l-HOP (oxaliplatin)
Study: 17414592
Drug: Ciprofibrate 100
Normalized name: ciprofibrate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofibrate 100 mg daily for 8 weeks
Study: 15121021
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg iv ibandronate injections
Study: 11262678
Drug: Telephone administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone administration of the VCM1 questionnaire
Study: 22972399
Drug: Low-dose atorvastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose atorvastatin (10 mg)
Study: 9476035
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 16 mg once daily
Study: 22309790
Drug: APBI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: APBI treatment
Study: 9288302
Drug: Both FES
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both FES and C‐L operations
Study: 17460370
Drug: Benidipine administered
Normalized name: manidipine
DrugBank: Manidipine (DB09238)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine administered first, then ARB increased (Group B)
Study: 30076171
Drug: ozanimod (treatment)
DrugBank: Ozanimod (DB12612)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ozanimod (treatment)
Study: 22717145
Drug: Therapist behaviours
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist behaviours in internet-delivered cognitive behaviour therapy (iCBT)
Study: 11823658
Drug: Intravenous tPA
Normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tPA
Study: 25025992
Drug: Pioglitazone 15-30
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15-30 mg/day added on calcium channel blockers (CCBs)
Study: 19250558
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (indapamide SR 1.5 mg +/‐ perindopril 2‐4 mg)
Study: 30218695
Drug: GFF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI (28.8 μg/10 μg)
Study: 30218695
Drug: GP MDI
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP MDI (14.4 μg)
Study: 22967772
Drug: Olanzapine treatment
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine treatment for 8 weeks
Study: 2262371
Drug: Six hyperthermia
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six hyperthermia treatments
Study: 30391912
Drug: Dexmedetomidine (Dex)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (Dex) administration (1 µg/kg loading dose before anaesthesia induction and 0.5 µg/kg/h infusion during surgery)
Study: 27206218
Drug: Pertuzumab plus
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab plus topotecan (1.25 mg/m days 1-5 every 3 weeks)
Study: 10391557
Drug: Intraoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiation therapy (IORT) of 12-25 Gy
Study: 29311072
Drug: Cefiderocol 500
Normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cefiderocol 500 mg
Study: 23964144
Drug: Whole dose
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole dose NaP preparation (compared to half-dose PEG plus bisacodyl)
Study: 2963205
Drug: Percutaneous oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous oestrogen therapy for 2 years, opposed by oral micronized progesterone (200 mg) during the second year
Study: 18547537
Drug: Retinal implants
Normalized name: retinaldehyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinal implants (neural retinal progenitor cell layers with retinal pigment epithelium)
Study: 21160192
Drug: Sustained-release dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sustained-release dinoprostone vaginal pessary followed 6 h later by high-dose oxytocin infusion
Study: 21160192
Drug: Sustained-release dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sustained-release dinoprostone vaginal pessary with concurrent high-dose oxytocin infusion
Study: 21160192
Drug: Sustained-release dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sustained-release dinoprostone pessary followed 6 h later by high-dose oxytocin
Study: 2683685
Drug: Self-instruction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-instruction treatment using a modified version of the LOGO computer language (REFLECT) and videotape feedback
Study: 16722837
Drug: Aspirin users
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin users
Study: 17215531
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of nevirapine
Study: 1506045
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of normal saline
Study: 7773815
Drug: Active motion
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active motion in combination with continuous passive motion (CPM)
Study: 31356973
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (CT)
Study: 25151042
Drug: Quadrivalent meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent meningococcal conjugate vaccine (MCV4) in PSV-exposed/MCV4 group
Study: 9525435
Drug: Cidofovir 5
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cidofovir 5 mg/kg once weekly for 2 weeks, then maintenance therapy with 5 mg/kg once every other week
Study: 26115690
Drug: Pulsed high-intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed high-intensity laser therapy (HILT) plus routine physical therapy program (RPTP)
Study: 11391598
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (Arm B) with partial response
Study: 9258754
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (400 IU daily for at least 2 years)
Study: 22800378
Drug: Department of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Department of Geriatrics (DG) treatment pathway including comprehensive geriatric assessment, pain relief, hydration, oxygenation, nutrition, elimination, prevention and management of delirium, assessment of falls and osteoporosis, early mobilization, and individualized rehabilitation plans.
Study: 22800378
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment in the Department of Orthopaedic Surgery (DOS).
Study: 19841897
Drug: Low-dose vasopressin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vasopressin (0.01-0.03 U/min)
Study: 8721275
Drug: Intracavernous administration
Normalized name: bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracavernous administration of moxisylyte with a tourniquet
Study: 8721275
Drug: Intracavernous administration
Normalized name: bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracavernous administration of moxisylyte without a tourniquet
Study: 18184934
Drug: Simplified version
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simplified version of a habit reversal treatment (awareness training, self-monitoring, competing responses, and social support)
Study: 8918509
Drug: Supportive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive group sessions and free nicotine supplementation (patches, chewing gum)
Study: 27998859
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate infusion
Study: 30962703
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical therapy
Study: 6983966
Drug: Carprofen 150
Normalized name: Carprofen
DrugBank: Carprofen (DB00821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carprofen 150 mg daily, b.i.d. administration
Study: 21114605
Drug: Linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 5 mg once daily
Study: 24491033
Drug: Paliperidone extended-release
Normalized name: Paliperidone Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone extended-release (ER)
Study: 22314630
Drug: Music intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Music intervention (20 minutes of standard postoperative care and music twice daily on postoperative days 2 through 4)
Study: 8330544
Drug: Sedation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation with midazolam or diazepam suspension
Study: 29672196
Drug: Synbiotic supplementation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplementation (twice a day for three months)
Study: 10499601
Drug: rV-CEA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rV-CEA vaccine
Study: 28396999
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg daily
Study: 9179279
Drug: High-dose Ara-C
Normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High-dose Ara-C (HDAC) combined with high dose mitoxantrone